Abbott Laboratories stock heads into the open after a modest loss
Published on 09/09/2026 at 05:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 8, 2026, Abbott Laboratories stock ended at USD 106.82 on the NYSE, down 1.4 percent for the session. According to MarketBeat data, the shares traded between USD 106.26 and USD 108.33 on the day, with volume broadly in line with recent averages. In the same session, the S&P 500 closed down 0.4 percent, underscoring that Abbott Laboratories moved roughly in step with the broader market.Zacks market wrap The stock also traded below a recent analyst target, as TD Cowen reiterated its buy rating and kept a USD 135 price objective on September 8, 2026, highlighting perceived upside versus the latest close.GuruFocus analyst note
September 8, 2026 in numbers
Abbott Laboratories Inc. (ISIN US0028241000, NYSE: ABT) closed at USD 106.82 on September 8, 2026, compared with an intraday high near USD 108.33 and a low around USD 106.26, placing the finish in the lower half of the session range.MarketBeat data Based on the reiterated TD Cowen target of USD 135 reported that day, the stock ended the session roughly USD 28 below that level, pointing to a double-digit percentage gap between the latest trading price and the analyst’s valuation view.GuruFocus analyst note Market data show that the broader S&P 500 index lost 0.4 percent to close at 7,718.41 on September 8, 2026, meaning Abbott Laboratories underperformed the benchmark marginally in percentage terms while still reflecting the day’s risk-off tone.Zacks market wrap
Today’s drivers to watch
Today, September 9, 2026, Abbott Laboratories enters the session without a fresh earnings release in the morning, so attention remains on how investors digest the recent TD Cowen reaffirmation of its buy stance and USD 135 price target from September 8, 2026, which frames expectations for medium-term performance.GuruFocus analyst note With the S&P 500 having declined in the previous session amid broader concerns captured in recent market wraps, Abbott Laboratories stock may be sensitive to any new macroeconomic headlines or sector developments that affect large health care constituents.Zacks market wrap Company guidance for full-year 2026 earnings per share, set in the July reporting cycle, continues to serve as a fundamental backdrop for how the market interprets any incremental news or analyst commentary in the days ahead.MarketBeat earnings summary
